CL2013001037A1 - Polipeptido gb de citomegalovirus (cmv) que comprende al menos un dominio extracelular de proteina gb; composicion inmunogénica que comprende el polipeptido gb de cmv; metodo para producir respuesta inmune contra cmv. - Google Patents

Polipeptido gb de citomegalovirus (cmv) que comprende al menos un dominio extracelular de proteina gb; composicion inmunogénica que comprende el polipeptido gb de cmv; metodo para producir respuesta inmune contra cmv.

Info

Publication number: CL2013001037A1
Authority: CL; Chile
Prior art keywords: cmv; polypeptide; cytomegalovirus; protein; immune response
Prior art date: 2010-10-15

Application number

CL2013001037A

Other languages

English (en)

Inventor

Guy Jean Marie Fernand Pierre Baudoux

Normand Blais

Martine Marchand

Original Assignee

Glaxosmithkline Biolog Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-15

Filing date

2013-04-15

Publication date

2013-08-30

2013-04-15 Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa

2013-08-30 Publication of CL2013001037A1 publication Critical patent/CL2013001037A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Biotechnology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)

CL2013001037A 2010-10-15 2013-04-15 Polipeptido gb de citomegalovirus (cmv) que comprende al menos un dominio extracelular de proteina gb; composicion inmunogénica que comprende el polipeptido gb de cmv; metodo para producir respuesta inmune contra cmv. CL2013001037A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US39341310P	2010-10-15	2010-10-15

Publications (1)

Publication Number	Publication Date
CL2013001037A1 true CL2013001037A1 (es)	2013-08-30

Family

ID=44789497

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013001037A CL2013001037A1 (es)	2010-10-15	2013-04-15	Polipeptido gb de citomegalovirus (cmv) que comprende al menos un dominio extracelular de proteina gb; composicion inmunogénica que comprende el polipeptido gb de cmv; metodo para producir respuesta inmune contra cmv.

Country Status (21)

Country	Link
US (1)	US20130216613A1 (es)
EP (1)	EP2627352B1 (es)
JP (1)	JP6138047B2 (es)
KR (1)	KR20130140009A (es)
CN (1)	CN103237560B (es)
AR (1)	AR083454A1 (es)
AU (1)	AU2011315447A1 (es)
BR (1)	BR112013008624B1 (es)
CA (1)	CA2813522C (es)
CL (1)	CL2013001037A1 (es)
CO (1)	CO6741153A2 (es)
CR (1)	CR20130191A (es)
DO (1)	DOP2013000080A (es)
ES (1)	ES2635014T3 (es)
IL (1)	IL225667A0 (es)
MA (1)	MA34802B1 (es)
MX (1)	MX2013004149A (es)
PH (1)	PH12013500724A1 (es)
SG (1)	SG189176A1 (es)
TW (1)	TW201305190A (es)
WO (1)	WO2012049317A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011053798A2 (en) *	2009-10-30	2011-05-05	The Administrators Of The Tulane Educational Fund	Peptide compositions and methods for inhibiting herpesvirus infection
HRP20211015T1 (hr)	2013-12-03	2021-10-01	Hookipa Biotech Gmbh	Cjepivo protiv citomegalovirusa (cmv)
CN106102769A (zh) *	2013-12-11	2016-11-09	促进军事医学的亨利·M·杰克逊基金会公司	人疱疹病毒三聚糖蛋白B、包含三聚gB的蛋白复合体及其作为疫苗的用途
EP3031822A1 (en) *	2014-12-08	2016-06-15	Novartis AG	Cytomegalovirus antigens
US10611800B2 (en)	2016-03-11	2020-04-07	Pfizer Inc.	Human cytomegalovirus gB polypeptide
WO2017153954A1 (en) *	2016-03-11	2017-09-14	Pfizer Inc.	Human cytomegalovirus gb polypeptide
CN106119286A (zh) *	2016-08-10	2016-11-16	吴江近岸蛋白质科技有限公司	表达载体及其高效表达和制备人胱抑素c蛋白的方法
BR112019020853A2 (pt)	2017-04-04	2020-05-12	Avidea Technologies, Inc.	Vacinas à base de peptídeo, métodos de fabricação e usos das mesmas para induzir uma resposta imune
BR112020004747A2 (pt)	2017-09-13	2020-09-24	Sanofi Pasteur	composição imunogênica de citomegalovírus humano
WO2020085457A1 (ja)	2018-10-25	2020-04-30	Ｋｍバイオロジクス株式会社	改変ＣＭＶｇＢタンパク質及びこれを含むＣＭＶワクチン
JP7179872B2 (ja) *	2018-12-10	2022-11-29	Ｋｍバイオロジクス株式会社	サイトメガロウイルスの先天性感染を予防又は治療するためのワクチン
US11629172B2 (en)	2018-12-21	2023-04-18	Pfizer Inc.	Human cytomegalovirus gB polypeptide
CN109627294B (zh) *	2018-12-29	2020-10-09	四川大学	一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用
EP4004018A1 (en)	2019-07-24	2022-06-01	GlaxoSmithKline Biologicals SA	Modified human cytomegalovirus proteins
US20230234992A1 (en)	2020-06-05	2023-07-27	Glaxosmithkline Biologicals Sa	Modified betacoronavirus spike proteins
WO2021250626A2 (en)	2020-06-12	2021-12-16	Glaxosmithkline Biologicals Sa	Dock tag system
US20230303637A1 (en)	2020-06-12	2023-09-28	Glaxosmithkline Biologicals Sa	Gbs ferritin nanoparticles
TWI810589B (zh)	2020-06-21	2023-08-01	美商輝瑞股份有限公司	人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
EP4237085A1 (en)	2020-10-28	2023-09-06	Sanofi Pasteur	Liposomes containing tlr4 agonist, preparation and uses thereof
JP2024535054A (ja) *	2021-09-16	2024-09-26	ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ	免疫原性組成物及びその使用
WO2023144665A1 (en)	2022-01-28	2023-08-03	Glaxosmithkline Biologicals Sa	Modified human cytomegalovirus proteins
CN115948468A (zh) *	2022-09-09	2023-04-11	青岛大学	一种人巨细胞病毒重组载体及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235877A (en)	1979-06-27	1980-11-25	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en)	1979-11-13	1983-02-08	Likhite Vilas V	Antigen compounds
IL61904A (en)	1981-01-13	1985-07-31	Yeda Res & Dev	Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en)	1982-05-26	1984-03-13	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
US4866034A (en)	1982-05-26	1989-09-12	Ribi Immunochem Research Inc.	Refined detoxified endotoxin
US6100064A (en) *	1984-04-06	2000-08-08	Chiron Corporation	Secreted viral proteins useful for vaccines and diagnostics
US4877611A (en)	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
CA1331443C (en)	1987-05-29	1994-08-16	Charlotte A. Kensil	Saponin adjuvant
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
DE69015222T2 (de)	1989-02-04	1995-05-04	Akzo Nv	Tocole als Impfstoffadjuvans.
ES2162139T5 (es)	1993-03-23	2008-05-16	Smithkline Beecham Biologicals S.A.	Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
CN1055093C (zh)	1993-11-17	2000-08-02	实验室奥姆公司	葡糖胺二糖类、其制备方法和用途、以及含有这些二糖的药物组合物
GB9409962D0 (en)	1994-05-18	1994-07-06	Smithkline Beecham Biolog	Novel compounds
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
SK18602000A3 (sk)	1998-06-08	2001-07-10	Sca Emballage France	Obal umožňujúci rýchle vyrovnanie
CZ302062B6 (cs)	1998-06-30	2010-09-22	Om Pharma	Derivát acyldipeptidu, zpusob jeho prípravy, meziprodukty pro jeho prípravu a farmaceutický prostredek, který ho obsahuje
DE19910044A1 (de) *	1999-03-08	2000-09-14	Bodo Plachter	Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
AU1581400A (en)	1999-12-22	2001-07-03	Om Pharma	Acyl pseudopeptides bearing a functionalised auxiliary spacer
ATE549031T1 (de) *	2007-09-21	2012-03-15	Sanofi Pasteur	Impfstoffzusammensetzung zur prävention von cmv- infektionen
WO2010089129A1 (en) *	2009-02-06	2010-08-12	Cormus Srl	Inhibitors of viral fusion and uses thereof
WO2011053798A2 (en) *	2009-10-30	2011-05-05	The Administrators Of The Tulane Educational Fund	Peptide compositions and methods for inhibiting herpesvirus infection
US20130196903A1 (en) *	2010-08-11	2013-08-01	Jv Bio Srl	Multimeric Inhibitors of Viral Fusion and Uses Thereof

2011
- 2011-10-14 AR ARP110103818 patent/AR083454A1/es unknown
- 2011-10-14 KR KR20137012553A patent/KR20130140009A/ko not_active Withdrawn
- 2011-10-14 MX MX2013004149A patent/MX2013004149A/es not_active Application Discontinuation
- 2011-10-14 US US13/879,438 patent/US20130216613A1/en not_active Abandoned
- 2011-10-14 CA CA2813522A patent/CA2813522C/en active Active
- 2011-10-14 SG SG2013023791A patent/SG189176A1/en unknown
- 2011-10-14 CN CN201180060437.9A patent/CN103237560B/zh active Active
- 2011-10-14 AU AU2011315447A patent/AU2011315447A1/en not_active Abandoned
- 2011-10-14 EP EP11768058.7A patent/EP2627352B1/en active Active
- 2011-10-14 WO PCT/EP2011/068040 patent/WO2012049317A2/en not_active Ceased
- 2011-10-14 JP JP2013533239A patent/JP6138047B2/ja active Active
- 2011-10-14 PH PH1/2013/500724A patent/PH12013500724A1/en unknown
- 2011-10-14 ES ES11768058.7T patent/ES2635014T3/es active Active
- 2011-10-14 MA MA35897A patent/MA34802B1/fr unknown
- 2011-10-14 TW TW100137497A patent/TW201305190A/zh unknown
- 2011-10-14 BR BR112013008624-6A patent/BR112013008624B1/pt active IP Right Grant
2013
- 2013-04-10 IL IL225667A patent/IL225667A0/en unknown
- 2013-04-12 DO DO2013000080A patent/DOP2013000080A/es unknown
- 2013-04-15 CL CL2013001037A patent/CL2013001037A1/es unknown
- 2013-04-25 CO CO13105813A patent/CO6741153A2/es not_active Application Discontinuation
- 2013-05-02 CR CR20130191A patent/CR20130191A/es unknown

Also Published As

Publication number	Publication date
KR20130140009A (ko)	2013-12-23
EP2627352A2 (en)	2013-08-21
EP2627352B1 (en)	2017-05-10
PH12013500724A1 (en)	2017-08-23
CA2813522C (en)	2022-06-21
MA34802B1 (fr)	2014-01-02
CA2813522A1 (en)	2012-04-19
CO6741153A2 (es)	2013-08-30
AU2011315447A1 (en)	2013-05-09
US20130216613A1 (en)	2013-08-22
WO2012049317A2 (en)	2012-04-19
MX2013004149A (es)	2013-09-02
IL225667A0 (en)	2013-06-27
BR112013008624B1 (pt)	2022-07-26
BR112013008624A2 (pt)	2021-05-11
JP6138047B2 (ja)	2017-05-31
AR083454A1 (es)	2013-02-27
CN103237560B (zh)	2016-05-11
SG189176A1 (en)	2013-05-31
DOP2013000080A (es)	2013-08-15
WO2012049317A3 (en)	2012-06-21
ES2635014T3 (es)	2017-10-02
TW201305190A (zh)	2013-02-01
CN103237560A (zh)	2013-08-07
JP2013544074A (ja)	2013-12-12
CR20130191A (es)	2013-06-28

Publication	Publication Date	Title
CL2013001037A1 (es)	2013-08-30	Polipeptido gb de citomegalovirus (cmv) que comprende al menos un dominio extracelular de proteina gb; composicion inmunogénica que comprende el polipeptido gb de cmv; metodo para producir respuesta inmune contra cmv.
FR24C1039I2 (fr)	2025-09-26	Compositions modulant l'expression de sod-1
IL211394B (en)	2018-07-31	Chimeric fusion proteins for inducing an immune response to p. gingivalis, preparations containing them and their uses
CL2014002903A1 (es)	2015-02-06	Composición geopolimérica de aluminosilicato; método de preparacion y sus usos.
EP2906258A4 (en)	2016-08-10	Compositions for modulating c9orf72 expression
HUE039747T2 (hu)	2019-02-28	Eljárások és kompozíciók EGFRVIII-ra való immunválasz indukálására
FR2998570B1 (fr)	2016-12-02	Peptides, compositions les comprenant et utilisations notamment cosmetiques propigmentantes
WO2014189973A3 (en)	2015-03-05	Anti-transferrin receptor antibodies and methods of use
CR20130529A (es)	2014-03-05	Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae
BRPI0708344B8 (pt)	2021-05-25	vetores adenovirais quiméricos e composição imunogênica
DK2726090T3 (da)	2020-01-20	Argininfri tnfr: fc-fusionspolypeptidsammensætninger
CA2893435C (en)	2024-11-12	IMMUNOGENE COMPOSITION
UY34406A (es)	2013-05-31	Compuestos y métodos para mejorar la respuesta inmune innata
FR2991662B1 (fr)	2014-06-13	Minimanche de pilotage d'un aeronef
BR112013030395A2 (pt)	2016-12-13	polipeptídeo, polinucleotídeo, vetor, composição imunogênica, vacina, e, uso de uma composição imunogênica
EP2796126A4 (en)	2015-07-15	OIL-IN-WATER EMULSION COMPOUND
IT1403806B1 (it)	2013-10-31	Composizione cosmetica.
CL2015001116A1 (es)	2015-09-25	Composición y uso de dimeros de alquil cetena hidrogenados.
LT2654785T (lt)	2019-07-10	Sustiprintas galvijų imuninis atsakas
EP2857000A4 (en)	2015-11-11	COSMETIC COMPOSITION WITH AN EMULSION
DK3656758T3 (da)	2024-04-22	Mellemprodukter til fremstilling af c-terminale hsp90-inhibitorer
TR201905787T4 (tr)	2019-05-21	Liyofilize TAT-NR2B9C formülasyonu.
CL2013001314A1 (es)	2014-02-14	Composicion de yogur de consistencia espesa que comprende microorganismos probióticos no replicantes.
CL2011002994A1 (es)	2012-07-20	Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
EP3075822A4 (en)	2017-05-17	Perfume composition